This report was undertaken to provide an updated estimate of costs related to HIV/AIDS in Canada, with a particular focus on the costs of treatment and costs associated with loss of productivity for lost work hours. It is a follow-up document to the 2001 study The Cost of HIV/AIDS in Canada by Colin Dodds, MA, Ronald Colman, PhD, Carol Amaratunga, PhD, and Jeff Wilson, BES, GPI Atlantic.
The Canadian AIDS Society (CAS) gratefully acknowledges Rx&D: Canada’s Research-Based Pharmaceutical Companies for their support and funding for the development and production of this paper, as well for their ongoing support to people living with HIV/AIDS.
Download the report: The Economic Cost of HIV/AIDS in Canada